QLIF-09. LONGTERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY

INTRODUCTION: Glioblastoma (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median surviva...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Rulseh, Aaron, Sroubek, Jan, Klener, Jan, Vymazal, Josef
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692852/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.819
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia